Market atlas / Amino-acid / glutathione / Taurine

Taurine (amino acid, aging research)

traditional-to-validatedsmall-moleculeamino-acidmitochondrial-support● taurine-levels

Stage by geography

Japan leads by 4 stages.

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSCNJPKR+4 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	consumer	not dated	not published
CN	RCT	2026-05-06	not published
JP	approved	2019-02-21	indication A drug with a new additional indication and a new dosage for the inhibition of stroke-like episodes in patients with mitochondrial myopathy, encephalopathy…
KR	signal	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Taurine, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Young Mania Rating Scale (YMRS; 11 item structured interview; Young et al 1978).	US
Scores on standardized measures of manic and depressive symptoms (HAM-D, MADRS, YMRS)	US
Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient…	US
Difference in Tumor Necrosis Factor Alpha (TNF-alpha) in Individuals With CBSDH Pre and Post Taurine Treatment.	US
Ankle-brachial index	CN
Changes of cognitive function assessed by cognitive function scale after 12 weeks.	CN
Rate of subjects whose CIS score has improved under 76 at week 4	KR

Connections

no connections yet

Trajectory

2010

ProfileTaurine (amino acid, aging research)

NCT01192828 · machine-extracted

2010

MarketUS: rct (clinical trials (highest phase 2))

NCT01192828 · machine-extracted

2019

MarketJP: approved-other (PMDA-approved (Japan))

PMDA:taurine (2019-02-21) · machine-extracted

2026

MarketCN: rct (clinical trials (highest phase 2))

NCT07567742 · machine-extracted

2026

MarketUS: consumer (US dietary supplement (DSHEA), not FDA-approved as a drug)

DSLD:294525 · machine-extracted

2026

MarketKR: signal (clinical trials (highest phase ?))

NCT02418130 · machine-extracted

Get into the weeds: raw observations + provenance

tau_facets  2026-06-29  kind=facets  verify=M
   Taurine facets
   source NCT01192828  https://clinicaltrials.gov/study/NCT01192828

tau_us_trial  2026-06-29  kind=geography_stage  verify=M
   Taurine: US phase 2 trials [NCT01192828]
   source NCT01192828  https://clinicaltrials.gov/study/NCT01192828

pmda__dev_taurine__JP  2026-07-13  kind=geography_stage  verify=M
   PMDA-approved in Japan: Taurine (Taurine powder 98% “Taisho” (Taisho Pharmaceutical Co., Ltd.)), first approval 2019-02-21. [PMDA List of Approved Drugs]
   source PMDA:taurine (2019-02-21)  https://www.pmda.go.jp/files/000281190.pdf

tau_cn  2026-06-29  kind=geography_stage  verify=M
   Taurine: registered phase 2 trials in China [NCT07567742]
   source NCT07567742  https://clinicaltrials.gov/study/NCT07567742

tau_us_consumer  2026-06-29  kind=geography_stage  verify=M
   Taurine sold as a US dietary supplement
   source DSLD:294525  https://dsld.od.nih.gov/label/294525

ctsearch__KR__dev_taurine  2026-07-10  kind=geography_stage  verify=M
   taurine: 1 registered trial(s) in KR, highest phase ? [NCT02418130]
   source NCT02418130  https://clinicaltrials.gov/study/NCT02418130